Vortioxetine | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Vortioxetine
US Exclusivities

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Metrochem Vortioxetine Hydrobromide

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Vortioxetine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

48 API Suppliers, 25 USDMF, 3 JDMF, 6 EU WC, 9 KDMF, 9 NDC API, 33 Listed Suppliers, $ API Reference Price

48 API Suppliers
25 USDMF
3 JDMF
6 EU WC
9 KDMF
9 NDC API
33 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

11 Intermediate Suppliers

11 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

84 FDF Dossiers, 18 FDA Orange Book, 30 Europe, 3 Canada, 20 South Africa, 13 Listed Dossiers

84 FDF Dossiers
18 FDA Orange Book
30 Europe
3 Canada
20 South Africa
13 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE

TABLET;ORAL - EQ 10MG BASE
TABLET;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 20MG BASE
TABLET;ORAL - EQ 5MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 2 DKSH, 2 Faran Shimi Pharmaceutical, 4 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 1 Clariant, 3 DFE Pharma, 4 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 5 Kerry, 9 Microlex e.U, 2 Pharmatrans-Sanaq, 2 Pluviaendo, 3 Prachin Chemical, 14 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Vasa Pharmachem

1 Rochem International Inc
14 SPI Pharma
2 DKSH
2 Faran Shimi Pharmaceutical
4 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 Pfanstiehl
3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 BASF
1 Clariant
3 DFE Pharma
4 Gangwal Chemicals
1 Ideal Cures Pvt Ltd
2 Ingredion Pharma Solutions
5 Kerry
9 Microlex e.U
2 Pharmatrans-Sanaq
2 Pluviaendo
3 Prachin Chemical
14 Roquette
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
9 Sigachi Industries
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

35 Fillers, Diluents & Binders, 17 Direct Compression, 17 Disintegrants & Superdisintegrants, 12 Taste Masking, 12 Chewable & Orodispersible Aids, 12 Thickeners and Stabilizers, 10 Lubricants & Glidants, 10 Co-Processed Excipients, 9 Granulation, 8 Coating Systems & Additives, 5 Parenteral, 4 Film Formers & Plasticizers, 3 Controlled & Modified Release, 2 Topical, 2 Coloring Agents, 2 Rheology Modifiers, 1 Solubilizers, 1 Surfactant & Foaming Agents, 1 Emulsifying Agents

35 Fillers, Diluents & Binders
17 Direct Compression
17 Disintegrants & Superdisintegrants
12 Taste Masking
12 Chewable & Orodispersible Aids
12 Thickeners and Stabilizers
10 Lubricants & Glidants
10 Co-Processed Excipients
9 Granulation
8 Coating Systems & Additives
5 Parenteral
4 Film Formers & Plasticizers
3 Controlled & Modified Release
2 Topical
2 Coloring Agents
2 Rheology Modifiers
1 Solubilizers
1 Surfactant & Foaming Agents
1 Emulsifying Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

1 Data Compilation #PharmaFlow
44 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 25 Regulatory FDF Prices, 17 Annual Reports

1 US Medicaid Prescriptions
25 Regulatory FDF Prices
17 Annual Reports

MARKET PLACE

8 APIs, 4 FDF Dossiers, 1 Intermediates

8 APIs
4 FDF Dossiers
1 Intermediates

PATENTS & EXCLUSIVITIES

80 US Patents, 8 US Exclusivities, 12 Health Canada Patents

80 US Patents
8 US Exclusivities
12 Health Canada Patents

REF. STANDARDS & IMPURITIES

8 Others

8 Others

$ API Ref.Price (USD/KG) : 3,482 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

8 All

01 8TAKEDA PHARMS USA

filter Product Reset all filters

8 All

01 8VORTIOXETINE HYDROBROMIDE

filter Exclusivity Expiration Date Reset all filters

8 All

01 42026-08-23

02 42027-02-23

filter Exclusivity Code Reset all filters

8 All

01 4M-232

02 4PED

Product Main Page

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

PED

Exclusivity Expiration Date

2027-02-23

Application Number

204447

Product Number

3

Exclusivity Details

01

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-02-23

Application Number : 204447

Product Number : 3

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

PED

Exclusivity Expiration Date

2027-02-23

Application Number

204447

Product Number

4

Exclusivity Details

02

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-02-23

Application Number : 204447

Product Number : 4

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

PED

Exclusivity Expiration Date

2027-02-23

Application Number

204447

Product Number

2

Exclusivity Details

03

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-02-23

Application Number : 204447

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

PED

Exclusivity Expiration Date

2027-02-23

Application Number

204447

Product Number

1

Exclusivity Details

04

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : PED

Exclusivity Expiration Date : 2027-02-23

Application Number : 204447

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

M-232

Exclusivity Expiration Date

2026-08-23

Application Number

204447

Product Number

4

Exclusivity Details

05

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : M-232

Exclusivity Expiration Date : 2026-08-23

Application Number : 204447

Product Number : 4

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

M-232

Exclusivity Expiration Date

2026-08-23

Application Number

204447

Product Number

3

Exclusivity Details

06

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : M-232

Exclusivity Expiration Date : 2026-08-23

Application Number : 204447

Product Number : 3

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

M-232

Exclusivity Expiration Date

2026-08-23

Application Number

204447

Product Number

1

Exclusivity Details

07

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : M-232

Exclusivity Expiration Date : 2026-08-23

Application Number : 204447

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

TAKEDA PHARMS USA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

VORTIOXETINE HYDROBROMIDE

Portfolio PDF

Product Web Link

Digital Content

Exclusivity Code

M-232

Exclusivity Expiration Date

2026-08-23

Application Number

204447

Product Number

2

Exclusivity Details

08

TAKEDA PHARMS USA

VORTIOXETINE HYDROBROMIDE

Peptide-Based Therapeutics Summit

Not Confirmed

TAKEDA PHARMS USA

Japan

Peptide-Based Therapeutics Summit

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

VORTIOXETINE HYDROBROMIDE

Exclusivity Code : M-232

Exclusivity Expiration Date : 2026-08-23

Application Number : 204447

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!